| 英文名稱 | NS-304 (Selexipag; ACT-293987) |
|---|---|
| 中文名稱 | 賽樂西帕 | 司來(lái)帕格 |
| CAS號(hào) | 475086-01-2 |
| 分子式 | C26H32N4O4S |
| 分子量 | 496.62 |
| 外觀 | White to yellow powder |
| 英文名稱 | NS-304 (Selexipag; ACT-293987) |
|---|---|
| 中文名稱 | 賽樂西帕 | 司來(lái)帕格 |
| CAS號(hào) | 475086-01-2 |
| 分子式 | C26H32N4O4S |
| 分子量 | 496.62 |
| 外觀 | White to yellow powder |
Selexipag, also known as ACT-293987 and NS-304, is a a first-in-class orally available selective non-prostanoid IP receptor agonist, which is currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679, are agonists at the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.